Abstract
Background
Methods
Results
Conclusion
Keywords
Abbreviations:
aUC (advanced urothelial carcinoma), ICI (immune checkpoint inhibitors), IRAEs (immune related adverse effects), LN (lymph node), MIBC (muscle-invasive bladder cancer), PDL1 (programmed death ligand 1), TME (tumor microenvironment)Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerReferences
- Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook.Ther Clin Risk Manag. 2018; 14 (Published 2018 Jun 5): 1019-1040https://doi.org/10.2147/TCRM.S158753
- Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma.N Engl J Med. 2020; 383: 1218-1230https://doi.org/10.1056/NEJMoa2002788
- Enfortumab vedotin in previously treated advanced urothelial carcinoma.N Engl J Med. 2021; 384: 1125-1135https://doi.org/10.1056/NEJMoa2035807
- Erdafitinib in locally advanced or metastatic urothelial carcinoma.N Engl J Med. 2019; 381: 338-348https://doi.org/10.1056/NEJMoa1817323
- TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors.J Clin Oncol. 2021; 39: 2474-2485https://doi.org/10.1200/JCO.20.03489
- Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.J Natl Cancer Inst. 2013; 105: 499-503https://doi.org/10.1093/jnci/djt015
- Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.J Clin Oncol. 2010; 28: 1850-1855https://doi.org/10.1200/JCO.2009.25.4599
- Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.J Clin Oncol. 1999; 17: 3173-3181https://doi.org/10.1200/JCO.1999.17.10.3173
- Five-factor prognostic model for survival of post-platinum patients with metastatic urothelial carcinoma receiving PD-L1 inhibitors [published correction appears in J Urol. 2021 Mar;205(3):942].J Urol. 2020; 204: 1173-1179https://doi.org/10.1097/JU.0000000000001199
- A new prognostic model in patients with advanced urothelial carcinoma treated with first-line immune checkpoint inhibitors.Eur Urol Oncol. 2021; 4: 464-472https://doi.org/10.1016/j.euo.2020.12.006
- A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma.Br J Cancer. 2020; 122: 555-563https://doi.org/10.1038/s41416-019-0686-0
Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. The Lancet. 2017;389:67-76. doi:10.1016/S0140-6736(16)32455-2.
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.Lancet Oncol. 2017; 18: 1483-1492https://doi.org/10.1016/S1470-2045(17)30616-2
- Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.Ann Oncol. 2019; 30: 970-976https://doi.org/10.1093/annonc/mdz127
Nelson AA, Cronk RJ, Lemke EA, et al. Early bone metastases are associated with worse outcomes in metastatic urothelial carcinoma. Bladder Cancer. 2021;7:33-42. doi:10.3233/BLC-200377.
- Impact of performance status on treatment outcomes: a real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.Cancer. 2020; 126: 1208-1216
- Histological subtypes and response to PD-1/PD-L1 blockade in advanced urothelial cancer: a retrospective study.J Urol. 2020; 204: 63-70
- Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.BJU Int. 2021; 128: 196-205
- The REDCap consortium: building an international community of software platform partners.J Biomed Inform. 2019; 95103208https://doi.org/10.1016/j.jbi.2019.103208
- Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support.J Biomed Inform. 2009; 42: 377-381
- Efficacy of enfortumab vedotin in advanced urothelial cancer: analysis from the urothelial cancer network to investigate therapeutic experiences (UNITE) study [published online ahead of print, 2021 Dec 9].Cancer. 2021; (10.1002/cncr.34057)https://doi.org/10.1002/cncr.34057
- Role of bone metastases in patients receiving immunotherapy for pre-treated urothelial carcinoma: the multicentre, retrospective meet-URO-1 bone study [published online ahead of print, 2021 Dec 16].Clin Genitourin Cancer. 2021; (00238-X): S1558-S7673https://doi.org/10.1016/j.clgc.2021.12.008
- Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer.Eur Urol. 2020; 77: 269-276https://doi.org/10.1016/j.eururo.2019.10.004
- Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.Urol Oncol Semin Orig Investig. 2021; 39 (e1-437.e9): 437https://doi.org/10.1016/j.urolonc.2021.01.006
- The cancer immunogram as a framework for personalized immunotherapy in urothelial cancer.Eur Urol. 2019; 75: 435-444https://doi.org/10.1016/j.eururo.2018.09.022
- The cancer immunogram: a pledge for a comprehensive biomarker approach for personalized immunotherapy in urothelial cancer.Eur Urol. 2019; 75: 445-447https://doi.org/10.1016/j.eururo.2018.12.005
- Evolution of PD-1 and PD-L1 gene and protein expression in primary tumors and corresponding liver metastases of metastatic bladder cancer.Eur Urol. 2018; 74: 527-529https://doi.org/10.1016/j.eururo.2018.06.028
- Integrative clinical and genomic characterization of mtap-deficient metastatic urothelial cancer.Eur Urol Oncol. 2021; 14 (Published online November)https://doi.org/10.1016/j.euo.2021.10.006
- Clonal evolution of chemotherapy-resistant urothelial carcinoma.Nat Genet. 2016; 48: 1490-1499https://doi.org/10.1038/ng.3692
- Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV201): a multicentre, single-arm, phase 2 trial [published correction appears in Lancet Oncol. 2021 Jun;22(6):e239].Lancet Oncol. 2021; 22: 872-882https://doi.org/10.1016/S1470-2045(21)00094-2
- Making patient-specific treatment decisions using prognostic variables and utilities of clinical outcomes.Cancers. 2021; 13https://doi.org/10.3390/cancers13112741
- Systemic immunity in cancer.Nat Rev Cancer. 2021; 21: 345-359https://doi.org/10.1038/s41568-021-00347-z
- Current perspectives on immunotherapy in the perioperative setting of muscle-infiltrating bladder cancer.Front Oncol. 2020; 10 (Published 2020 Oct 21)568279https://doi.org/10.3389/fonc.2020.568279
- Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma.N Engl J Med. 2021; 384: 2102-2114https://doi.org/10.1056/NEJMoa2034442
- Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma.N Engl J Med. 2020; 383: 1218-1230https://doi.org/10.1056/NEJMoa2002788
- Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): a multicenter phase 2 trial.J Clin Oncol. 2021; 39 (4504): 4504https://doi.org/10.1200/JCO.2021.39.15_suppl.4504
- Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB trial.J Clin Oncol. 2020; 38 (542): 542https://doi.org/10.1200/JCO.2020.38.6_suppl.542
- Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.Nat Med. 2020; 26: 1839-1844https://doi.org/10.1038/s41591-020-1085-z
- A phase Ib/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC).Ann Oncol. 2018; 29: viii726https://doi.org/10.1093/annonc/mdy424.039